1 / 18

Drug appropriateness criteria: potential for indications creep

Drug appropriateness criteria: potential for indications creep. Amy Lodolce, PharmD, BCPS Mike Koronkowski, PharmD. Learning Objectives. Describe off-label drug use and populations where it is most prevalent Explain the key components of appropriate use criteria for drugs

forrester
Download Presentation

Drug appropriateness criteria: potential for indications creep

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Drug appropriateness criteria: potential for indications creep Amy Lodolce, PharmD, BCPS Mike Koronkowski, PharmD

  2. Learning Objectives • Describe off-label drug use and populations where it is most prevalent • Explain the key components of appropriate use criteria for drugs • Judge the appropriateness of a given drug for an off-label use • Justify whether or not the formulary should restrict drugs based on indications

  3. Issues surrounding off-label prescribing • Legality • Prevalence • Level of evidence • Potential risks to patients • Cost to healthcare system

  4. How common is this? • 21% (150 million) of 725 million prescriptions • 73% (109 million) little or no scientific support • 27% (41 million) strong scientific evidence Ann Intern Med 2006;166:1021-6.

  5. Which patients? • Children • Patients with HIV • Patients with psychiatric disorders • Pregnant women Ann Intern Med 2006;166:1021-6.

  6. Which drugs? • Anticonvulsants (notably gabapentin) • Antiasthmatic medications • Cardiac drugs • Antibiotics Ann Intern Med 2006;166:1021-6.

  7. Examples • Gabapentin • Botulinum toxin type A (Botox)

  8. Level of evidence Tertiary: • Drugdex on Micromedex • AHFS (the formulary service) Secondary: • Medline Primary: • Critically evaluate a trial

  9. Potential harms • Adverse drug reactions • Potential for polypharmacy • Cost to healthcare system

  10. Role of the pharmacist As defined by ASHP: • Patient advocate, drug info specialist • Evaluate orders (policies and procedures) • Proactive approaches to promote informed decisions by third-party payers (http://www.ashp.org/s_ashp/bin.asp?CID=1276&DID=5393&DOC=FILE.PDF)

  11. Medication use policy • Evaluate medications (MUE) formally and report to P&T committee • P&T can restrict or limit use, but this is difficult for certain classes of drugs • State of Illinois Department of Healthcare and Family Services criteria

  12. Medication Use Evaluation • MUE Goal – provide pts. with safe and effective drug therapy • Accomplished through assessment and improvement of medication use process • Focus can be single drug or therapeutic class OR component of medication use process/outcomes

  13. Medication Use Evaluation • Objectives of MUE • Improve medication use process • Reduce medication-related problems • Reduce cost through appropriate use criteria • Provide education to staff

  14. Medication Use Evaluation Step 1 • Form the committee • Multidisciplinary • Can be a sub-committee of P&T • Assign responsibility

  15. Medication Use Evaluation Step 2 • Choose a topic • Focus on high volume, high risk, problem-prone medications • Can also focus on aspect of medication use process • Overall, topics should be selected to cover the scope of the institution

  16. Medication Use Evaluation Step 3 • Develop criteria (methods) • Standards that define performance expectations • Phrase explicitly (yes/no) • Evidence based • Define outcomes • Indicators

  17. Medication Use Evaluation Steps 4 and 5 • Develop data collection form • User friendly • Many boxes to check vs. free response • Collect data • Prospective • Concurrent • Retrospective

  18. Medication Use Evaluation Step 6 • Data analysis Step 7 • Corrective action • Education • Guidelines/clinical pathway • Restrictive approach

More Related